10-K: Exicure, Inc. Reports Full Year 2024 Results, Navigates Strategic Shift and Financial Challenges

Exicure, Inc. reports its full year 2024 results, highlighting a strategic shift towards exploring growth opportunities and addressing significant financial challenges, including a going concern uncertainty.

Summary

• Exicure, Inc., historically a biotechnology company, has shifted its focus to exploring strategic alternatives to maximize stockholder value.
• In 2024, the company received $500,000 from a patent licensing agreement and $2.137 million in other income from asset sales.
• The company obtained significant financing late in 2024 through stock purchase agreements with HiTron, SangSang, and MIRTO.
• As of March 12, 2025, HiTron beneficially owns 53% of the outstanding shares of Common Stock.
• On January 19, 2025, Exicure acquired GPCR Therapeutics USA Inc. and entered into a License and Collaboration Agreement with GPCR Therapeutics Inc.
• The company is exploring growth through acquisitions and transactions, potentially focusing on opportunities in Asia.
• Exicure faces challenges in maintaining its Nasdaq listing, including compliance with minimum bid price and stockholders' equity requirements.
• The company has a history of losses and expects to continue incurring significant losses, raising substantial doubt about its ability to continue as a going concern.
• As of December 31, 2024, cash and cash equivalents were approximately $12.5 million.
• The company is involved in ongoing legal proceedings, including a securities class action lawsuit and shareholder derivative lawsuits.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a history of losses, a going concern warning, and challenges in maintaining Nasdaq listing compliance. While there are some positive developments, the overall outlook is negative.

Positives

• The company secured significant financing in late 2024 through stock purchase agreements.
• Exicure is actively exploring strategic alternatives to enhance stockholder value.
• The acquisition of GPCR Therapeutics USA Inc. and the collaboration agreement with GPCR Therapeutics Inc. may provide future growth opportunities.
• The court entered final judgment approving the settlement in the securities class action and the settlement will be fully covered by insurance.

Negatives

• The company has a history of significant operating losses and expects to continue incurring losses.
• There is substantial doubt about Exicure's ability to continue as a going concern.
• The company faces challenges in maintaining its Nasdaq listing.
• The company is involved in ongoing legal proceedings.
• The company identified material weaknesses in its internal control over financial reporting.

Risks

• The exploration of strategic alternatives may not be successful.
• The company needs to obtain substantial funding to continue operations.
• The common stock may be delisted from Nasdaq.
• The company has a history of losses and may never achieve profitability.
• Internal computer systems may fail or suffer security breaches.
• Turnover of the board and senior management could impair the ability to implement the business plan.
• The influence of significant stockholders could make the Common Stock less attractive to some investors or otherwise harm the trading price of our Common Stock.
• The market price of the common stock has been, and is likely to continue to be, highly volatile, and you may not be able to resell your shares at or above the price you paid for them.

Future Outlook

Exicure expects to continue exploring strategic alternatives and will require additional financing to fund operations and pursue potential transactions. The company's future financial performance is substantially dependent on the results of its ongoing exploration of strategic alternatives.

Industry Context

Exicure's shift from biotechnology to exploring strategic transactions reflects a trend among smaller companies to seek growth and stability through mergers, acquisitions, or reverse mergers. The company's focus on Asia aligns with the increasing importance of Asian markets in the global economy.

Comparison to Industry Standards

• Given Exicure's shift in business strategy, direct comparison to industry standards is challenging.
• However, the company's need for additional financing and its exploration of strategic alternatives are common among small-cap companies in the biotechnology sector facing financial difficulties.
• Companies like Athersys and Heat Biologics have also explored strategic alternatives after facing challenges in their core business.
• Exicure's focus on Asian markets mirrors the strategies of companies like BeiGene and Hutchison China MediTech, which have successfully leveraged opportunities in China and other Asian countries.

Management Changes

Legal Proceedings

• Exicure is involved in a securities class action lawsuit, which is expected to be covered by insurance.
• The company is also involved in shareholder derivative lawsuits, which are currently stayed.
• A former employee filed a complaint against the company and its executives related to the former employee's separation from the company.

Related Party Transactions

• The company entered into a consulting agreement with Alta Companies LTD, where Paul Kang, a director of the Company, is the President.
• The company executed a promissory note with DGP, a related party.

Stakeholder Impact

• Shareholders face significant risks, including potential delisting, dilution, and loss of investment.
• Employees face uncertainty due to the company's financial challenges and strategic shift.
• The company's ability to meet its obligations to creditors is uncertain.

Next Steps

• Continue exploration of strategic alternatives.
• Seek additional financing to fund operations and potential transactions.
• Address material weaknesses in internal control over financial reporting.
• Comply with Nasdaq listing requirements.

Key Dates